Spots Global Cancer Trial Database for Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
Official Title: A Phase Ⅱ, Multicenter Open-label Study to Investigate the Efficacy and Safety of HL-085 Combined With Vemurafenib in Patients With Metastatic Colorectal Cancer (mCRC)
Study ID: NCT05233332
Conditions
Study Description
Brief Summary: The study consists of the two parts, phase IIa and phase IIb.
Detailed Description: The study consists of the two parts, phase IIa and phase IIb. Phase IIa study is to assess the safety and the antitumor activity in patients with mCRC and to recommend reasonable dosage regimen of HL-085 for phase IIb study. Phase IIb is a pivotal study to evaluate HL-085 plus Vemurafenib in patients with BRAFV600E mCRC whose disease has progressed after 1 or 2 prior regimens in the metastatic setting.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beijing Oncology Hospital, Beijing, Beijing, China
Contact Details
Name: Hongqi Tian, Ph.D
Affiliation: Shanghai Kechow Pharma, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
